We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
Read MoreHide Full Article
Incyte Corporation (INCY - Free Report) is scheduled to release fourth-quarter 2020 and full-year results on Feb 9, before market open.
The company has a disappointing track record. In the last reported quarter, the company missed earnings estimates by 68.06%. It missed earnings expectations in the last four quarters by 917.49%, on average.
Incyte Corporation Price, Consensus and EPS Surprise
Incyte primarily derives product revenues from sales of Jakafi in the United States and Iclusig. Patient demand for its lead drug, Jakafi, a first-in-class JAK1/JAK2 inhibitor, in all approved indications (polycythemiavera, myelofibrosis and refractory acute graft-versus-host disease [GVHD]) was strong in the previous quarter, a trend that most likely continued in the to-be-reported quarter. Jakafi sales grew 13% in the third quarter and the fourth quarter has most likely witnessed a sequential increase. The Zacks Consensus Estimate for Jakafi sales stands at $506 million.
The company also earns product royalty revenues from Novartis AG (NVS - Free Report) for the commercialization of Jakafi in ex-U.S. markets. Novartis recorded 24% growth in sales to $376 million in the fourth quarter and hence Incyte has most likely received higher royalties for the same.
We remind investors that while Jakafi sales and royalties are key catalysts for the company’s revenue growth, Iclusig sales and Olumiant royalties from Eli Lilly also contribute to the top line. Hence, these are likely to have aided the company’s revenues in the to-be-reported quarter. Net product revenues of Iclusig amounted to $26.3 million in the previous quarter and similar or higher levels of contribution are likely to have been witnessed in the to-be reported quarter. The Zacks Consensus Estimate for Iclusig sales stands at $25.5 million.
Olumiant product royalty revenues came in at $28.6 million in the previous quarter, up 32% year over year and similar levels of growth are likely to have boosted the top line in the to-be reported quarter.
Last April, the FDA approved Pemazyre (pemigatinib), a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma. Sales in the previous quarter came in at $8.1 million and the fourth quarter has most likely witnessed a sequential increase.
In May, the FDA approved Tabrecta (capmatinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC), whose tumors have a mutation that leads to MET exon 14 skipping (METex14) as detected by an FDA-approved test. Its partner Novartis has exclusive worldwide development and commercialization rights to Tabrecta. Royalties from the same might have resulted in incremental sales in the fourth quarter.
However, operating expenses increased in the previous quarter due to an increase in R&D expenses and selling, general and administrative expenses, a trend that most likely continued in the fourth quarter.
Key Pipeline Updates
Apart from the regular top and bottom-line numbers, we expect investors to focus on the company’s pipeline updates.
In November 2020, Incyte and Eli Lilly announced that the FDA issued an Emergency Use Authorization (EUA) for the distribution and emergency use of baricitinib to be used in combination with Gilead’s remdesivir in hospitalized adult and pediatric patients two years of age or older with suspected or laboratory confirmed COVID-19 who require supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). An update on the same is expected on the call.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Incyte this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP for Incyte is -11.73%.
Zacks Rank: The company currently carries a Zacks Rank #3.
Share Price Performance
Incyte’s stock has gained 4.6% in the year so far compared with the industry’s 8.6% growth.
Stocks to Consider
Here are a few stocks you may want to consider, as our model shows that these have the right combination of an earnings beat.
Seagen, Inc. has an Earnings ESP of +4.81% and a Zacks Rank #3.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
Incyte Corporation (INCY - Free Report) is scheduled to release fourth-quarter 2020 and full-year results on Feb 9, before market open.
The company has a disappointing track record. In the last reported quarter, the company missed earnings estimates by 68.06%. It missed earnings expectations in the last four quarters by 917.49%, on average.
Incyte Corporation Price, Consensus and EPS Surprise
Incyte Corporation price-consensus-eps-surprise-chart | Incyte Corporation Quote
Factors to Note
Incyte primarily derives product revenues from sales of Jakafi in the United States and Iclusig. Patient demand for its lead drug, Jakafi, a first-in-class JAK1/JAK2 inhibitor, in all approved indications (polycythemiavera, myelofibrosis and refractory acute graft-versus-host disease [GVHD]) was strong in the previous quarter, a trend that most likely continued in the to-be-reported quarter. Jakafi sales grew 13% in the third quarter and the fourth quarter has most likely witnessed a sequential increase. The Zacks Consensus Estimate for Jakafi sales stands at $506 million.
The company also earns product royalty revenues from Novartis AG (NVS - Free Report) for the commercialization of Jakafi in ex-U.S. markets. Novartis recorded 24% growth in sales to $376 million in the fourth quarter and hence Incyte has most likely received higher royalties for the same.
We remind investors that while Jakafi sales and royalties are key catalysts for the company’s revenue growth, Iclusig sales and Olumiant royalties from Eli Lilly also contribute to the top line. Hence, these are likely to have aided the company’s revenues in the to-be-reported quarter. Net product revenues of Iclusig amounted to $26.3 million in the previous quarter and similar or higher levels of contribution are likely to have been witnessed in the to-be reported quarter. The Zacks Consensus Estimate for Iclusig sales stands at $25.5 million.
Olumiant product royalty revenues came in at $28.6 million in the previous quarter, up 32% year over year and similar levels of growth are likely to have boosted the top line in the to-be reported quarter.
Last April, the FDA approved Pemazyre (pemigatinib), a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma. Sales in the previous quarter came in at $8.1 million and the fourth quarter has most likely witnessed a sequential increase.
In May, the FDA approved Tabrecta (capmatinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC), whose tumors have a mutation that leads to MET exon 14 skipping (METex14) as detected by an FDA-approved test. Its partner Novartis has exclusive worldwide development and commercialization rights to Tabrecta. Royalties from the same might have resulted in incremental sales in the fourth quarter.
However, operating expenses increased in the previous quarter due to an increase in R&D expenses and selling, general and administrative expenses, a trend that most likely continued in the fourth quarter.
Key Pipeline Updates
Apart from the regular top and bottom-line numbers, we expect investors to focus on the company’s pipeline updates.
In November 2020, Incyte and Eli Lilly announced that the FDA issued an Emergency Use Authorization (EUA) for the distribution and emergency use of baricitinib to be used in combination with Gilead’s remdesivir in hospitalized adult and pediatric patients two years of age or older with suspected or laboratory confirmed COVID-19 who require supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). An update on the same is expected on the call.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Incyte this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP for Incyte is -11.73%.
Zacks Rank: The company currently carries a Zacks Rank #3.
Share Price Performance
Incyte’s stock has gained 4.6% in the year so far compared with the industry’s 8.6% growth.
Stocks to Consider
Here are a few stocks you may want to consider, as our model shows that these have the right combination of an earnings beat.
Moderna (MRNA - Free Report) has an Earnings ESP of +0.57% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Seagen, Inc. has an Earnings ESP of +4.81% and a Zacks Rank #3.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>